not-yet-known not-yet-known not-yet-known unknown
All participants(N = 17) | OFC results | p-value | ||
---|---|---|---|---|
Positive(n = 6) | Negative(n = 11) | |||
Participants consenting to both serum and saliva collection, n | 9 | 4 | 5 | 0.62 |
Participants consenting to saliva but not serum collection, n | 8 | 2 | 6 | 0.62 |
Female, % | 58.8 | 50.0 | 63.6 | 0.64 |
Age (months), median (IQR) | 15 (13–17) | 15 (12–20) | 15 (13–17) | 0.84 |
Height (cm), median (IQR) | 76.0 (75.1–78.3) | 76.6 (73.7–82.8) | 76.0 (75.2–78.2) | 0.84 |
Weight (kg), median (IQR) | 9.3 (8.7–10.1) | 9.5 (8.4–11.9) | 9.3 (8.6–10.0) | 0.61 |
Peripheral blood eosinophils (cells/μL), median (IQR) | 290 (146–475) | 321 (150–531) | 262 (146–475) | 0.73 |
Serum total IgE (IU/mL) | 4.0 (0.0–14.0) | 13.2 (0.0–36.2) | 0.0 (0.0–8.9) | 0.11 |
Egg yolk-specific IgE (kUA/L), median (IQR) | 0.0 (0.0–0.33) | 0.17 (0.0–0.34) | 0.0 (0.0–0.35) | 0.55 |
Egg white-specific IgE (kUA/L), median (IQR) | 0.0 (0.0–1.21) | 0.97 (0.0–1.40) | 0.0 (0.0–1.13) | 0.16 |
Duration between last symptom of FPIES due to egg yolk and OFC (weeks), median (IQR) | 29 (25–37) | 28 (21–42) | 30 (25–36) | 0.91 |
Time to symptom onset at OFC (minutes), median (IQR) | 206.5 (165–240) | |||
IgE-dependent symptoms at OFC, % | 0 | 0 | 0 | 1.00 |